Olema Pharmaceuticals Q3 2023 Earnings Report

Olema Pharmaceuticals EPS Results

• Actual EPS: -$0.48
• Consensus EPS: -$0.51
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Olema Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Olema Pharmaceuticals Announcement Details

• Quarter: Q3 2023
• Date: 11/7/2023
• Time: N/A
• Conference Call Date: Tuesday, November 7, 2023
• Conference Call Time: 7:00AM ET

Olema Pharmaceuticals (NASDAQ:OLMA) is a clinical‐stage biopharmaceutical company headquartered in Redwood City, California, focused on developing novel small‐molecule therapies for the treatment of hormone receptor–positive (HR+) breast cancer and other estrogen‐driven malignancies. The company’s pipeline leverages a proprietary platform for designing oral selective estrogen receptor degraders (SERDs) that aim to overcome resistance mechanisms associated with existing endocrine therapies. Olema’s research and development facilities are complemented by strategic collaborations with academic institutions and contract research organizations across North America and Europe.

At the center of Olema’s development efforts is its lead candidate, OLP‐108, an orally bioavailable SERD engineered to bind and degrade the estrogen receptor with improved pharmacokinetic properties relative to first‐generation agents. Preclinical studies have demonstrated potent antitumor activity in models of both treatment‐naïve and endocrine‐resistant HR+ breast cancer. In addition, Olema is advancing a preclinical portfolio of next‐generation endocrine modulators that exploit complementary mechanisms of action, including selective estrogen receptor modulators (SERMs) and combination regimens with CDK4/6 inhibitors.

Since its founding in 2019, Olema Pharmaceuticals has grown from a small discovery team to a fully integrated development organization with discovery, translational biology and clinical operations capabilities. The company’s management has filed multiple investigational new drug (IND) applications and initiated Phase 1 and Phase 2 clinical trials in the United States. Olema also maintains a presence in Europe to support multinational studies and regulatory interactions with the European Medicines Agency (EMA).

Under the leadership of Chief Executive Officer Lindsey Rolfe, a biotech veteran with over 20 years of experience in oncology drug development, Olema continues to expand its scientific advisory board and executive team. The company’s leadership includes experts in medicinal chemistry, pharmacology and clinical oncology, all working toward the common goal of delivering new oral therapies that address unmet needs in breast cancer treatment and beyond.